resveratrol has been researched along with bmn 673 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pai Bellare, G; Sankar Patro, B | 1 |
| Chatterjee, S; Das, B; Dash, SR; Dhal, AK; Kundu, CN; Paul, S; Sinha, S | 1 |
2 other study(ies) available for resveratrol and bmn 673
| Article | Year |
|---|---|
Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Mice, SCID; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-akt; Resveratrol; Xenograft Model Antitumor Assays | 2022 |
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Apoptosis; Cell Line, Tumor; Curcumin; DNA; Humans; Mice; Mouth Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Resveratrol; Ribose | 2022 |